GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 3, 2015, Pages e39-e41

  Karmon, Sharon L ^a,b   Mohri, Hiroshi ^a   Spreen, William ^c   Markowitz, Martin ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOTEGRAVIR; COMPLEMENTARY DNA; INTEGRASE; PLASMID DNA; VIRUS DNA; VIRUS ENZYME; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDONE DERIVATIVE;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; CLADISTICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; EC50; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LETTER; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOTYPING; VIRUS RECOMBINANT; CLASSIFICATION; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; VIROLOGY;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIDONES;

EID: 84923701359     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000469     Document Type: Letter

References (16)

1. Roehr B. FDA approves first drug to prevent HIV infection. BMJ. 2012; 345: e4879.
2. Plosker GL. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Drugs. 2013; 73: 279-291.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363: 2587-2599.
4. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367: 411-422.
5. Marrazzo J, Ramjee G, Nair G. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; February 28-March 6, 2013; Atlanta, GA.
6. Spreen W, Ford SL, Chen S, et al. Pharmacokinetics, safety and tolerability of the HIV integrase inhibitor S/GSK1265744 long acting parenteral nanosuspension following single dose administration to healthy adults [Abstract no. TUPE040]. Paper presented at: XIX International AIDS Conference; July 20-25, 2012; Washington, DC.
7. Spreen WR, Margolis DA, Pottage JC Jr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013; 8: 565-571.
8. Andrews CD, Spreen WR,Mohri H, et al. Longacting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014; 343: 1151-1154.
9. Andrews CD, Spreen W, Yueh YL, et al. GSK1265744 long-acting protects macaques against repeated high-dose intravaginal challenges. Paper presented at: 21st Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA.
10. Markowitz M, Evering TH, Garmon D, et al. A Randomized Open-Label Study of 3-versus 5-Drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2014; 66: 140-147.
11. Baalwa J, Wang S, Parrish NF, et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology. 2013; 436: 33-48.
12. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012; 490: 417-420.
13. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/ founder viruses in acute and early HIV-1 infection. J Exp Med. 2009; 206: 1273-1289.
14. Low A, Prada N, Topper M, et al. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother. 2009; 53: 4275-4282.
15. Mohammed KD, Topper MB, Muesing MA. Sequential deletion of the integrase (Gag-Pol) carboxyl terminus reveals distinct phenotypic classes of defective HIV-1. J Virol. 2011; 85: 4654-4666.
16. Reuman EC, Bachmann MH, Varghese V, et al. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother. 2010; 54: 934-936